EUVIMEDEUVIMED entdecken
Crossref

Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy

Zhenmei Yang, Ying Liu, Kun Zhao, Weiqiang Jing, Lin Gao, Xianghui Dong, Yan Wang, Maosen Han, Chongdeng Shi, Chunwei Tang, Peng Sun, Rui Zhang und 5 weitere

Journal of Controlled Release · 2023-08 · 360 · 718-733

DOI: 10.1016/j.jconrel.2023.07.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-08. Verfasst von Zhenmei Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Departmen…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptors, Chimeric Antigen, Liver Neoplasms. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a prevalent and lethal disease, and tumor regression rarely occurs in advanced HCC patients due to limited effective therapies. Given the enrichment of macrophages in HCC and their role in tumor immunity, transforming them into chimeric antigen receptor macrophages (CAR-Ms) is thought to increase HCC cell-directed phagocytosis and tumoricidal immunity. To test this hypothesis, mRNA encoding CAR is encapsulated in a lipid nanoparticle (LNP) that targets liver macrophages. Notably, the LNPs adsorb specific plasma proteins that enable them to target HCC-associated macrophages. Moreover, mRNA encoding Siglec-G lacking ITIMs (Siglec-GΔITIMs) is codelivered to liver macrophages by LNP to relieve CD24-mediated CAR-Ms immune suppression. Mice treated with LNPs generating CAR-Ms as well as CD24-Siglec-G blockade significantly elevate the phagocytic function of liver macrophages, reduce tumor burden and increase survival time in an HCC mouse model. Arguably, our work suggests an efficacious and flexible strategy for the treatment of HCC and warrants further rigorous evaluation in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularReceptors, Chimeric AntigenLiver NeoplasmsMiceAnimalsCell Line, TumorImmunotherapyMacrophagesPhagocytosisSialic Acid Binding Immunoglobulin-like Lectins

Stichwörter der Autor:innen

CD24Chimeric antigen receptor macrophageHepatocellular carcinomaLipid nanoparticleProtein corona

Substanzen

Receptors, Chimeric AntigenSialic Acid Binding Immunoglobulin-like Lectins

Autor:innen und Institutionen

  • NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College…
  • Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Cultural West Road, Shandong Province 250012, China.
  • Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China.
  • Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, 4572A Academic Building, Clear Water Bay, Kowloon, 999077, Hong Kong, China.
  • Key Laboratory for Experimental Teratology of Ministry of Education, Key Laboratory of Infection and Immunity of Shandong Province and Department of Immunology, School of Basic Medical Sciences, Cheeloo Medical College…

Zitieren

APA

Yang, Z., Liu, Y., Zhao, K., Jing, W., Gao, L., Dong, X., Wang, Y., Han, M., Shi, C., Tang, C., Sun, P., Zhang, R., Fu, Z., Zhang, J., Zhu, D., Chen, C., & Jiang, X. (2023). Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. Journal of Controlled Release, 360, 718-733. https://doi.org/10.1016/j.jconrel.2023.07.021

Vancouver

Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. Journal of Controlled Release. 2023;360:718-733. doi:10.1016/j.jconrel.2023.07.021

BibTeX
@article{Yang2023,
  author = {Yang, Zhenmei and Liu, Ying and Zhao, Kun and Jing, Weiqiang and Gao, Lin and Dong, Xianghui and Wang, Yan and Han, Maosen and Shi, Chongdeng and Tang, Chunwei and Sun, Peng and Zhang, Rui and Fu, Zhipeng and Zhang, Jing and Zhu, Danqing and Chen, Chen and Jiang, Xinyi},
  title = {Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {360},
  pages = {718--733},
  doi = {10.1016/j.jconrel.2023.07.021}
}
Kostenlos starten →